Incyte does TGF-beta differently
Four months after yielding first-in-human data INCA33890 enters phase 3.
ASCO GI – Jazz sees a new Ziihera Herizon
But Tevimbra’s role looks shaky as adverse events loom.
Christmas oncology roundup
The holiday period included Genmab’s discontinuation of acasunlimab.
The conjugate enthusiasm bypasses Mythic
The private ADC company is being wound down.
Lung toxicity deaths halt ifinatamab
Ideate-Lung02 goes on global clinical hold.
Ringside sends Immunome towards filing
On a cross-trial basis varegacestat beats Ogsiveo.
SABCS 2025 – Carrick sees a way forward in CDK7
The group will start a pivotal trial of samuraciclib following promising second-line results.
